New drugs from multinational pharmaceutical companies such as Otezla, Cotellic, and Erievedge, which were not properly introduced in the domestic market, left the Korean market one after another this year. It is believed that it has made significant sales overseas but has decided to withdraw due to lack of marketability in Korea.

According to the MFDS on the 7th, Roche voluntarily dropped two types of anticancer drugs, Cotellic and Erievedge, in the first half of the year. The licenses for Cotellic and Erievedge were revoked as of June 23 and April 7. Erivedge is a skin cancer treatment approved by the MFDS in 2013. It is used to treat metastatic basal cell cancer that cannot be operated or radiated. It